Virtual reality could revolutionize how we measure vision loss

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 50 years * Sufficient knowledge of the French language * Ability to give personal, express, free, and informed consent * Ability to comply with the requirements of the protocol * Person covered by Social Security * Clarity of the ocular environment, adequate pupil dilation to allow the collection of good quality images, as determined by the investigator Additional inclusion criteria for group 1, healthy subjects: * No detectable visual pathologies * Best monocular visual acuity ≥ 8/10 Additional inclusion criteria for group 2, subjects with LMA, early AMD, or intermediate AMD without atrophy: * Diagnosis of AMD, early AMD, or intermediate AMD * Absence of geographic atrophy * Presence of drusen (diameter \> 63 µm) with or without pigmentary changes Additional inclusion criteria for group 3, subjects with dry AMD with perifoveal atrophy: * Diagnosis of atrophic AMD * Presence of drusen (diameter \> 125 µm) * Location of geographic atrophy as determined by the investigator: extrafoveal, juxtafoveal * Preservation of central vision confirmed by the investigator based on a comprehensive and integrated interpretation of SD-OCT, FAF, retinography, and best corrected visual acuity examinations. Additional inclusion criteria for group 4, Subject with dry AMD with foveal atrophy: * Diagnosis of atrophic AMD * Presence of drusen (diameter \> 125 µm) * Investigator's localization of geographic atrophy: retrofoveal * Central vision impairment confirmed by the investigator based on a comprehensive and integrated interpretation of SD-OCT, FAF, retinography, and best corrected visual acuity examinations. Exclusion Criteria: * Pregnant women, women in labor, or breastfeeding women * Subjects undergoing drug treatments that may cause motor, visual, vestibular, or cognitive disorders (PSA, neuroleptics, etc.) or that could interfere with the study examinations * Any concomitant intraocular condition in the eye being studied (e.g., glaucoma or cataract) * Any retinal pathology that could cause retinal atrophy other than AMD (eliminate dystrophy, chronic CRSC, pachyatrophy, resorption of vitelliform material with atrophy, high myopia, etc.) * Known systemic disease that, in the investigator's opinion, would prevent active participation in the study * Participation in any other therapeutic study evaluating a drug. * Subjects with cognitive impairment, illiterate subjects, and subjects who do not speak the national language. * Persons subject to enhanced protection or legal safeguards (guardianship, trusteeship).